卵巢透明细胞癌 (OCCC) 是一种组织学亚型，在亚洲国家约占上皮性卵巢癌病例的 20%，但在西方国家发病率相对较低。同时，透明细胞肾细胞癌（ccRCC）是肾癌的主要亚型。 OCCC 和 ccRCC 在组织学上彼此相似，并且具有清晰的细胞质外观。研究揭示了 OCCC 和 ccRCC 之间的一些遗传相似性。然而，有关这些癌症之间常见生物学背景因素的信息仍然很少。例如，细胞脂滴的积累被证明在 ccRCC 进展中发挥着至关重要的作用，而 OCCC 则缺乏类似的信息。在这篇前瞻性文章中，我们提出脂滴可能是未来探索的候选者，以更好地了解 OCCC 和 ccRCC 之间的共同生物学背景，从而可能导致亚型特异性治疗策略。我们进一步讨论了聚 ADP-核糖聚合酶抑制治疗与脂质代谢之间的关系，因为这种治疗策略作为上皮性卵巢癌的治疗方法引起了相当大的关注。版权所有 © 2024 Koizume、Takahashi 和 Miyagi。

Ovarian clear cell carcinoma (OCCC) is a histological subtype that constitutes approximately 20% of epithelial ovarian cancer cases in Asian countries, but has a relatively low incidence in Western countries. Meanwhile, clear cell renal cell carcinoma (ccRCC) is a major subtype of kidney cancer. OCCC and ccRCC resemble one another histologically and have clear cytoplasmic appearances. Studies have revealed some genetic similarities between OCCC and ccRCC. However, information regarding common biological background factors between these cancers remains scarce. For example, accumulation of cellular lipid droplets was shown to play a crucial role in ccRCC progression, while similar information is lacking for OCCC. In this perspective article, we propose that lipid droplets may be candidates for future exploration to better understand the common biological backgrounds between OCCC and ccRCC, potentially leading to subtype-specific treatment strategies. We further discuss the relationship between poly ADP-ribose polymerase inhibition treatment and lipid metabolism because this therapeutic strategy has attracted considerable attention as a treatment for epithelial ovarian cancer.Copyright © 2024 Koizume, Takahashi and Miyagi.